A5067313194- Prostate Cancer Treatment and Research
- CAR-T cell therapy research
- Hemoglobinopathies and Related Disorders
- Immunotherapy and Immune Responses
- Iron Metabolism and Disorders
- Prostate Cancer Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Blood groups and transfusion
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- Neurofibromatosis and Schwannoma Cases
- Quinazolinone synthesis and applications
- Neuroblastoma Research and Treatments
- DNA Repair Mechanisms
- Chronic Myeloid Leukemia Treatments
- Synthesis and Characterization of Heterocyclic Compounds
- Radiopharmaceutical Chemistry and Applications
- Hormonal and reproductive studies
- Cancer Immunotherapy and Biomarkers
- T-cell and B-cell Immunology
- Sarcoma Diagnosis and Treatment
- Blood disorders and treatments
- Glycosylation and Glycoproteins Research
- Genetic factors in colorectal cancer
- Radiation Effects in Electronics
University of Washington
2022-2025
Center for Cancer Research
2020-2024
Fred Hutch Cancer Center
2023-2024
National Cancer Institute
2020-2024
Memorial Sloan Kettering Cancer Center
2016-2021
SUNY Downstate Health Sciences University
2019-2021
National Institutes of Health
2020
Kings County Hospital Center
2020
State University of New York
2019
Abstract The major histocompatibility complex I (MHC-1) presents antigenic peptides to tumor-specific CD8+ T cells. regulation of MHC-I by kinases is largely unstudied, even though many patients with cancer are receiving therapeutic kinase inhibitors. Regulators cell-surface HLA amounts were discovered using a pooled human kinome shRNA interference–based approach. Hits scoring highly subsequently validated additional RNAi and pharmacologic MAP2K1 (MEK), EGFR, RET as negative regulators...
PURPOSE There are limited data available on the real-world patterns of molecular testing in men with advanced prostate cancer. We thus sought to evaluate next-generation sequencing (NGS) United States, focused single versus serial NGS testing, different disease states (hormone-sensitive v castration-resistant, metastatic vs nonmetastatic), tissue plasma circulating tumor DNA (ctDNA) assays, and how often actionable were found each test. METHODS The Prostate Cancer Precision Medicine...
PURPOSE Outcomes data for DNA-damaging therapeutics men with prostate cancer (PC) and non- BRCA1/2 homologous recombination repair (HRR) mutations are limited. We evaluated outcomes by HRR alteration in PC treated poly(ADP-ribose)polymerase inhibitors (PARPi) and/or platinum chemotherapy. METHODS Retrospective from the PROMISE consortium were used. Clinical differences assessed between patients BRCA1/ 2 (cohort A) those without direct BRCA complex interaction B: ATM, CDK12, CHEK1, CHEK2,...
While
Immunotherapeutic strategies targeting B-cell acute lymphoblastic leukemia (B-ALL) effectively induce remission; however, disease recurrence remains a challenge. Due to the potential for antigen loss, diminution, lineage switch or development of secondary treatment-related malignancy, phenotype and manifestation subsequent may be elusive. We report on two patients with multiply relapsed/refractory B-ALL who, following chimeric receptor T-cell therapy, developed myeloid malignancies. In first...
Abstract Background AR gene alterations can develop in response to pressure of testosterone suppression and androgen receptor targeting agents (ARTA). Despite this, the relevance these context ARTA treatment clinical outcomes remains unclear. Methods Patients with castration-resistant prostate cancer (CRPC) who had undergone genomic testing received were identified Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) database. stratified according timing...
Hematopoietic stem cell transplant (HSCT) is the only cure for patients with sickle disease (SCD). Although most SCD experience progressive end-organ damage and shortened lifespans, not all follow same course, tempo, or outcome. Therefore, dilemma facing physicians weighing selection of timing procedure against donor type transplant-related mortality morbidity that go up increasing age. On other hand, families how acceptable HSCT carries some risks to them. We have analyzed chronic...
Ever since evidence about the increased risk of stent thrombosis with drug eluting stents (DES) surfaced in 2005, Food and Drug Administration (FDA) has recommended use dual antiplatelet therapy (aspirin P2Y12 inhibitor) following DES placement. The PLATO trial demonstrated lower mortality rates Ticagrelor when compared to clopidogrel (9.8% vs. 11.7%, p<0.001) treating patients acute coronary syndrome. Given their pleiotropic benefits, statins are today second most prescribed United States...
5055 Background: LuPSMA, a radioligand targeting the cell surface protein PSMA, is approved for men with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) following an androgen receptor (AR)-signaling inhibitor (ARSI) and docetaxel. DNA damage repair gene (DDR) mutations are common in mCRPC, given that ionizing radiation induces damage, we hypothesized presence of these alterations could associate improved clinical outcomes to LuPSMA. Data also suggests DDR may correlate...
128 Background: LuPSMA, a radioligand therapy targeting the cell surface protein PSMA, is approved for men with PSMA-positive mCRPC previously treated androgen receptor signaling inhibitor (ARSI) and taxane chemotherapy. Several PARP inhibitors (PARPi) are also currently patients harboring alterations in genes associated DNA damage repair (DDR). Given that both therapeutics result damage, we hypothesized there would be clinical evidence of cross-resistance between two classes agents,...
Background: Rheumatoid arthritis (RA) patients have an increased risk of malignancy with postulated factors that include chronic inflammation, smoking and the use immunosuppressants been as drivers higher malignancies rates. Our study aimed to describe prevalence type encountered in urban, predominantly Black RA patient population. Methods: Cross sectional analysis 1142 diagnosis by ICD-codes which 501 cases met inclusion criteria for study. Blacks accounted 88.4% Fifty-six had cancer...